{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:19Z","timestamp":1753893019819,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"Background<\/jats:title>Prescription drug misuse (PDM), which involves the overprescription or inappropriate use of medications such as opioids, benzodiazepines, and stimulants, is one of the primary drivers of the opioid crisis. Identifying and understanding the most cost-effective interventions for preventing PDM is crucial.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To conduct a systematic review to identify and synthesize recent cost-effectiveness studies of interventions to prevent PDM.<\/jats:p><\/jats:sec>Search methods<\/jats:title>We searched MEDLINE, EMBASE, Scopus, PsycINFO, EconLit, and Tufts CEA Registry from January 2019 until June 2024 to identify cost-effectiveness or cost-utility analyses.<\/jats:p><\/jats:sec>Selection criteria<\/jats:title>We included comprehensive economic evaluations addressing our research PICO question.<\/jats:p><\/jats:sec>Data collection and analysis<\/jats:title>Two reviewers independently screened and selected studies for inclusion, extracted study information, and assessed the quality of all included studies. The findings were synthesized narratively to provide a comprehensive overview.<\/jats:p><\/jats:sec>Main results<\/jats:title>We identified eight recent interventions of fair to good quality that focus on addressing PDM, but none of them addressed benzodiazepines or stimulants. These interventions involved modifications in prescribing behavior, distribution of naloxone in community pharmacies, the use of medication for opioid use disorder with \u201ctreatment add-ons,\u201d and education-based strategies. Variations in time horizons, comparison groups, and modeling assumptions led to differences in cost-effectiveness and quality-adjusted life years (QALYs). Nonetheless, all interventions were deemed cost-effective, particularly from a healthcare perspective.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Evidence suggests that while the identified interventions for preventing PDM are cost-effective, their scope remains limited. Further research is needed to address the misuse of other prescription drugs and to evaluate the cost-effectiveness of Prescription Drug Monitoring Programs (PDMPs), particularly their impact on clinicians\u2019 prescribing practices for patients with chronic opioid use. Additionally, incorporating societal perspectives in future studies will be crucial to enhancing policy decisions and developing comprehensive strategies to combat prescription drug misuse globally.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1514851","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:18:31Z","timestamp":1741108711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effective interventions to prevent prescription drug misuse: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"L. Yesenia","family":"Rodr\u00edguez-Tanta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Summers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadia T.","family":"Shaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"year":"2019","key":"ref1"},{"year":"2018","author":"Seth","key":"ref2"},{"year":"2024","key":"ref3"},{"volume-title":"Prescription stimulant misuse and prevention among youth and young adults","year":"2021","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Med Care"},{"year":"2023","key":"ref6"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/15360288.2015.1101641","article-title":"Economic burden of prescription opioid misuse and abuse: a systematic review","volume":"29","author":"Oderda","year":"2015","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1192\/bjo.2023.515","article-title":"A systematic review of economic evaluations for opioid misuse, cannabis and illicit drug use prevention","volume":"9","author":"Faller","year":"2023","journal-title":"BJPsych Open"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jval.2024.02.004","article-title":"Economic evaluations of establishing opioid overdose prevention centers in 12 north American cities: a systematic review","volume":"27","author":"Behrends","year":"2024","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.jval.2020.03.015","article-title":"Economic evaluation of interventions to address opioid misuse: a systematic review of methods used in simulation modeling studies","volume":"23","author":"Barbosa","year":"2020","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"108928","DOI":"10.1016\/j.jsat.2022.108928","article-title":"Systematic review of the efficacy, effectiveness, and cost-effectiveness of stepped-care interventions for the prevention and treatment of problematic substance use","volume":"144","author":"Morse","year":"2023","journal-title":"J Subst Abus Treat"},{"year":"2024","key":"ref12"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","article-title":"Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report","volume":"24","author":"Lena","year":"2021","journal-title":"Value Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jval.2019.12.002","article-title":"Cost-effectiveness of intranasal naloxone distribution to high-risk prescription opioid users","volume":"23","author":"Acharya","year":"2020","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/17151635241228241","article-title":"An economic evaluation of community pharmacy-dispensed naloxone in Canada","volume":"157","author":"Cid","year":"2024","journal-title":"Can Pharm J CPJ Rev Pharm Can RPC"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e231080","DOI":"10.1001\/jamahealthforum.2023.1080","article-title":"Cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids","volume":"4","author":"Claypool","year":"2023","journal-title":"JAMA Health Forum"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/add.15879","article-title":"Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis","volume":"117","author":"Savinkina","year":"2022","journal-title":"Addict Abingdon Engl"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jval.2020.12.002","article-title":"Cost-effectiveness of an opioid abuse-prevention program using the narcotics information management system in South Korea","volume":"24","author":"Kim","year":"2021","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40273-019-00847-9","article-title":"The value of shorter initial opioid prescriptions: a simulation evaluation","volume":"38","author":"Bjarnad\u00f3ttir","year":"2020","journal-title":"Pharmaco Econ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/add.14668","article-title":"Cost-effectiveness of electronic- and clinician-delivered screening, brief intervention and referral to treatment for women in reproductive health centers","volume":"114","author":"Olmstead","year":"2019","journal-title":"Addict Abingdon Engl"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103953","DOI":"10.1016\/j.drugpo.2023.103953","article-title":"A population-based study on the risk of prescription opioid abuse in patients with chronic opioid use and cost-effectiveness of prescription drug monitoring program using a patient simulation model in South Korea","volume":"112","author":"Kim","year":"2023","journal-title":"Int J Drug Policy"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12954-024-01026-6","article-title":"Reducing overdose deaths among persons with opioid use disorder in Connecticut","volume":"21","author":"Scheidell","year":"2024","journal-title":"Harm Reduct J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.drugpo.2019.07.031","article-title":"Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States","volume":"75","author":"Townsend","year":"2020","journal-title":"Int J Drug Policy"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"DHHS"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/pm\/pnac068","article-title":"Changes in opioid dispensing by medical specialties after the release of the 2016 CDC guideline for prescribing opioids for chronic pain","volume":"23","author":"Salvatore","year":"2022","journal-title":"Pain Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 opioid guideline","volume":"169","year":"","journal-title":"Ann Internal Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/pharma2040030","article-title":"Helpful, unnecessary, or harmful: a systematic review of the effects of prescription drug monitoring program use on opioid prescriptions","volume":"2","author":"Smith","year":"2023","journal-title":"Pharmacoepidemiology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"109887","DOI":"10.1016\/j.drugalcdep.2023.109887","article-title":"Prescription drug monitoring programs evaluation: a systematic review of reviews","volume":"247","author":"Tay","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/epirev\/mxaa002","article-title":"Prescription drug monitoring programs and prescription opioid-related outcomes in the United States","volume":"42","author":"Puac-Polanco","year":"2020","journal-title":"Epidemiol Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1377\/hlthaff.2018.0512","article-title":"Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions","volume":"37","author":"Bao","year":"2018","journal-title":"Health Aff"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12913-023-09272-3","article-title":"The prescription drug monitoring program in a multifactorial approach to the opioid crisis: PDMP data, Pennsylvania, 2016-2020","volume":"23","author":"Adalbert","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jama.2015.12397","article-title":"Addressing the opioid epidemic","volume":"314","author":"Nelson","year":"2015","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1514851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:18:33Z","timestamp":1741108713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1514851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":37,"alternative-id":["10.3389\/fpubh.2025.1514851"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1514851","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1514851"}}